Drug intelligence / Profile preview

RGN-6669

Development stage: Preclinical
Lead developer: Rigerna Therapeutics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

RGN-6669 is an early-stage, liver-targeted small interfering RNA (siRNA) therapeutic being developed for the treatment of cardiovascular, metabolic, or respiratory diseases. It utilizes a proprietary liver-targeted GalNAc delivery technology to facilitate efficient in vivo delivery to hepatocytes. Originally developed by Rigerna, the global rights for the development, manufacturing, and commercialization of RGN-6669 were licensed to Hisun in October 2026.

Beyond the preview

Go deeper on RGN-6669.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGN-6669.